Louis Tharp, cofounder and executive director of the Global Healthy Living Foundation, discusses lessons learned from international experience with biosimilar uptake.
Transcript:
What have we learned about the uptake of biosimilars in other nations?
We’ve learned a lot about biosimilars from Europe and from Asia. They’ve been there for at least a decade. But, when it comes to the uptake in the United States, there isn’t as much we can learn because, in Europe and in Asia, they had a more direct way to influence the uptake of biosimilars. That usually occurred because, in many countries, there is a single government entity that’s responsible for buying the drugs. That’s not true in the United States.
In the United States we have a lot of choice, and it’s often times theoretical choice because while there are a lot of advertisements about drugs of all types, our insurance companies help us make the choice—to be kind—by looking primarily at cost. Physicians also direct us. So, where we might have a choice of say 9 biologics for an autoimmune disease, or 2 or 3 biologics for a cancer condition, [but] our physician or our insurance company may drive us to one drug.
We wind up in the same situation that Europe is in, but we get there in a very different way. The difference here—and the important part—is that psychologically, the patient doesn’t get to the same place as the patient in Europe does. Because the patient in Europe walks into the physician’s office, is diagnosed, gets a drug, and begins the treatment.
In the United States, there is a lot more perceived choice and a lot more perceived power on the part of the patient because of all of the advertising that we have now. And so, the patient needs to be able to understand the bigger picture and be able to have confidence in and get behind the treatment protocol that she winds up ultimately getting. And that’s one of the key issues that we deal with within the 50-State Network, which is groups of patient advocates all around the United States, as well as CreakyJoints, the arthritis side of the [Global Healthy Living Foundation]. The objective here is to help the patient understand the bigger picture and help the patient ultimately do well on the drug that they wind up being prescribed.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.